- FDA sends two warnings to companies selling unapproved CBD products
- Two companies selling unapproved cannabidiol (CBD) products including for the treatment of opioid addiction, have been handed warning letters from the FDA.
- to two companies for illegally selling unapproved products containing
- This action is part of the FDA’s efforts to pursue companies that illegally market CBD products with claims that they can treat medical conditions including opioid addiction or as an alternative to opioids.
Read full article: europeanpharmaceuticalreview.com